RecruitingNCT04510766
Tumor Molecular Profiling in Early Phase Clinical Trials
Molecular Characterization of Solid Tumors and Lymphomas to Optimize the Drug Development Process and Patients Enrollment in Early Phase Clinical Trials
Sponsor
Oncology Institute of Southern Switzerland
Enrollment
40 participants
Start Date
Oct 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Male or female patients age at least 18 years.
- Patients with histological diagnosis of advanced solid tumor or lymphoma who are potential candidates for early phase clinical trials.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Live expectancy of at least 6 months.
- Availability of FFPE archival tumor tissue from previous surgery or diagnostic biopsy adequate for molecular analysis.
- Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure.
- Willing and able to comply with study procedures
Exclusion Criteria2
- Presence of any clinical (e.g. concomitant disease, clinically significant symptoms, or non-clinical (psychological or social) conditions that would not make the patient eligible for enrolment in an early phase clinical trial.
- Any other active malignancy (other than the one for which the subject is being assessed for trial option) that is progressing or requiring active treatment with the exception of basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04510766
Related Trials
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT0509813227 locations
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT0563564316 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226712 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT0699702921 locations